Systemic and pulmonary hypertension, diabetes, and heart failure are among the diseases associated with endothelial dysfunction and reduced NO-cGMP signalling that may treatable by modulators of this pathway such as IW-1973, a clinical-stage sGC stimulator. This evidence concerns the gene SGCB and pulmonary arterial hypertension.